Scaling precision medicine requires industrialization

Benchwork can certainly be compelling, particularly in the precision medicine space — where new insights are gleaned on how individual biochemistries influence disease. But in order to make personalization a reality, bespoke therapies need to be industrialized, according to Amy DuRoss, CEO of Vineti, a software company that focuses on streamlining the back end of advanced therapies.

As she points out in a new First Opinion for STAT, breakthrough techs like CAR-T therapy may inspire us, but they are “unsustainably expensive, difficult to manufacture, and complicated to deliver.” The solution, she writes, is to standardize how individualized medicine is developed — so it can be scaled.